Mersana Therapeutics
Stock Forecast, Prediction & Price Target
Mersana Therapeutics Financial Estimates
Mersana Therapeutics Revenue Estimates
Mersana Therapeutics EBITDA Estimates
Mersana Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $43K N/A | $26.58M 61716.27% | $36.85M 38.65% | Avg: $33.12M Low: $29.22M High: $35.73M avg. -10.12% | Avg: $31M Low: $13.87M High: $47.41M avg. -6.41% | Avg: $29.91M Low: $13.38M High: $45.75M avg. -3.50% | Avg: $278.05M Low: $124.44M High: $425.29M avg. 829.53% |
Net Income
% change YoY
| $-169.20M N/A | $-207.54M -22.65% | $-171.67M 17.28% | Avg: $-96.96M Low: $-104.50M High: $-42.96M avg. 43.51% | Avg: $-112.39M Low: $-121.91M High: $-30.18M avg. -15.91% | Avg: $-86.50M Low: $-146.05M High: $-24.38M avg. 23.03% | Avg: $11.61M Low: $3.27M High: $19.60M avg. 113.42% |
EBITDA
% change YoY
| $-168.85M N/A | $-203.76M -20.67% | $-166.08M 18.49% | Avg: $-30.89M Low: $-33.33M High: $-27.26M avg. 81.39% | Avg: $-28.91M Low: $-44.23M High: $-12.94M avg. 6.41% | Avg: $-27.90M Low: $-42.68M High: $-12.48M avg. 3.50% | Avg: $-259.37M Low: $-396.72M High: $-116.08M avg. -829.53% |
EPS
% change YoY
| -$2.4 N/A | -$2.22 7.49% | -$1.48 33.33% | Avg: -$0.73 Low: -$0.9 High: -$0.37 avg. 50.61% | Avg: -$0.76 Low: -$1.05 High: -$0.26 avg. -3.29% | Avg: -$0.75 Low: -$1.26 High: -$0.21 avg. 1.32% | Avg: $0.1 Low: $0.03 High: $0.17 avg. 113.42% |
Operating Expenses
% change YoY
| $168.90M N/A | $230.34M 36.38% | $36.85M -84.00% | Avg: $5.88B Low: $5.19B High: $6.35B avg. 15870.46% | Avg: $5.50B Low: $2.46B High: $8.42B avg. -6.41% | Avg: $5.31B Low: $2.37B High: $8.12B avg. -3.50% | Avg: $49.40B Low: $22.11B High: $75.57B avg. 829.53% |
FAQ
What is Mersana Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 41.01% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -104.50M, average is -96.96M and high is -42.96M.
What is Mersana Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 202.37% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $29.22M, average is $33.12M and high is $35.73M.
What is Mersana Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 40.51% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$0.9, average is -$0.73 and high is $-0.37.
What is the best performing analyst?
In the last twelve months analysts have been covering Mersana Therapeutics stock. The most successful analyst is Edward White.